Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Harvard Medical School, Boston, MA, United States.
Centre hospitalier de l'Université de Montréal, Montreal, QC, United States.
Front Immunol. 2018 Jun 18;9:895. doi: 10.3389/fimmu.2018.00895. eCollection 2018.
Effective antiretroviral therapy (ART) has prevented the progression to AIDS and reduced HIV-related morbidities and mortality for the majority of infected individuals. However, a lifelong administration of ART is necessary, placing an inordinate burden on individuals and public health systems. Therefore, discovering therapeutic regimens able to eradicate or functionally cure HIV infection is of great importance. ART interruption leads to viral rebound highlighting the establishment and maintenance of a latent viral reservoir compartment even under long-term treatment. Follicular helper CD4 T cells (TFH) have been reported as a major cell compartment contributing to viral persistence, consequent to their susceptibility to infection and ability to release replication-competent new virions. Here, we discuss the molecular profiles and potential mechanisms that support the role of TFH cells as one of the major HIV reservoirs.
有效的抗逆转录病毒疗法(ART)已阻止了艾滋病的进展,并降低了大多数感染者的与 HIV 相关的发病率和死亡率。然而,ART 的终生治疗是必要的,这给个人和公共卫生系统带来了巨大的负担。因此,发现能够根除或功能性治愈 HIV 感染的治疗方案非常重要。ART 中断会导致病毒反弹,这突出表明即使在长期治疗下,潜伏病毒储存库隔间也得以建立和维持。滤泡辅助性 CD4 T 细胞(TFH)已被报道为有助于病毒持续存在的主要细胞隔间之一,这是由于它们易感染和能够释放具有复制能力的新病毒。在这里,我们讨论了支持 TFH 细胞作为主要 HIV 储存库之一的分子特征和潜在机制。